[go: up one dir, main page]

NO20010291D0 - Co-administration of ACAT and MMP inhibitors for the treatment of atherosclerotic wounds - Google Patents

Co-administration of ACAT and MMP inhibitors for the treatment of atherosclerotic wounds

Info

Publication number
NO20010291D0
NO20010291D0 NO20010291A NO20010291A NO20010291D0 NO 20010291 D0 NO20010291 D0 NO 20010291D0 NO 20010291 A NO20010291 A NO 20010291A NO 20010291 A NO20010291 A NO 20010291A NO 20010291 D0 NO20010291 D0 NO 20010291D0
Authority
NO
Norway
Prior art keywords
acat
atherosclerotic
wounds
administration
treatment
Prior art date
Application number
NO20010291A
Other languages
Norwegian (no)
Other versions
NO20010291L (en
Inventor
Thomas Michael Andrew Bocan
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20010291D0 publication Critical patent/NO20010291D0/en
Publication of NO20010291L publication Critical patent/NO20010291L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO20010291A 1998-07-21 2001-01-18 Co-administration of ACAT and MMP inhibitors for the treatment of atherosclerotic wounds NO20010291L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (2)

Publication Number Publication Date
NO20010291D0 true NO20010291D0 (en) 2001-01-18
NO20010291L NO20010291L (en) 2001-01-18

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010291A NO20010291L (en) 1998-07-21 2001-01-18 Co-administration of ACAT and MMP inhibitors for the treatment of atherosclerotic wounds

Country Status (25)

Country Link
EP (1) EP1098662A2 (en)
JP (1) JP2002521328A (en)
KR (1) KR20010083134A (en)
CN (1) CN1310629A (en)
AP (1) AP2001002035A0 (en)
AU (1) AU4701799A (en)
BG (1) BG105162A (en)
BR (1) BR9912296A (en)
CA (1) CA2335062A1 (en)
CZ (1) CZ2001126A3 (en)
EA (1) EA200100153A1 (en)
EE (1) EE200100046A (en)
HR (1) HRP20010055A2 (en)
HU (1) HUP0102880A3 (en)
ID (1) ID30030A (en)
IL (1) IL140982A0 (en)
IS (1) IS5809A (en)
NO (1) NO20010291L (en)
OA (1) OA11584A (en)
PL (1) PL346011A1 (en)
SK (1) SK502001A3 (en)
TR (1) TR200100205T2 (en)
WO (1) WO2000004892A2 (en)
YU (1) YU3501A (en)
ZA (1) ZA200100294B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1414848A (en) * 1999-11-05 2003-04-30 沃尼尔·朗伯公司 Prevention of plaque rupture by ACAT inhibitors
CO5261615A1 (en) 1999-12-01 2003-03-31 Agouron Pharma COMPOUNDS, COMPOSITIONS AND METHODS TO STIMULATE THE GROWTH AND ELONGATION OF NEURONS
JP2003534239A (en) * 1999-12-17 2003-11-18 ヴァージコア・インコーポレーテッド Novel succinate compounds, compositions, and methods of use and preparation
MXPA03001857A (en) * 2000-09-01 2003-06-04 Sankyo Co MEDICINAL COMPOSITIONS.
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
DE60321775D1 (en) * 2002-04-03 2008-08-07 Topotarget Uk Ltd CARBOXIC ACID DERIVATIVES CONTAIN A PIPERAZINE COMPOUND AS HDAC INHIBITORS
KR101011373B1 (en) * 2002-07-11 2011-01-28 비큐론 파마슈티컬스 인코포레이티드 N-hydroxyamide derivative having antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (en) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 Use of group of carbamyl phenylsulfonyl compounds
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (en) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 The effective extract component of river hazel and its application in prevention and treatment atherosclerosis
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
CZ26198A3 (en) * 1995-08-04 1998-07-15 Warner-Lambert Company Use of amidosulphuric acid derivatives, acylsulphonamides or sulphonylcarbamates for the manufacture of a drug with lipoprotein lowering effects
ES2167733T3 (en) * 1996-05-17 2002-05-16 Warner Lambert Co BIFENYLSULFONAMIDE MATRIX METALOPROTEINASE INHIBITORS.
CA2256716A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses

Also Published As

Publication number Publication date
YU3501A (en) 2005-06-10
ZA200100294B (en) 2002-01-10
OA11584A (en) 2004-07-20
AP2001002035A0 (en) 2001-03-31
PL346011A1 (en) 2002-01-14
HRP20010055A2 (en) 2002-04-30
HUP0102880A2 (en) 2002-06-29
WO2000004892A2 (en) 2000-02-03
CZ2001126A3 (en) 2002-01-16
CN1310629A (en) 2001-08-29
WO2000004892A3 (en) 2000-05-18
EA200100153A1 (en) 2001-08-27
IL140982A0 (en) 2002-02-10
EP1098662A2 (en) 2001-05-16
KR20010083134A (en) 2001-08-31
JP2002521328A (en) 2002-07-16
BR9912296A (en) 2001-04-17
EE200100046A (en) 2002-06-17
ID30030A (en) 2001-11-01
AU4701799A (en) 2000-02-14
BG105162A (en) 2001-12-29
SK502001A3 (en) 2002-06-04
HUP0102880A3 (en) 2002-11-28
TR200100205T2 (en) 2001-05-21
IS5809A (en) 2001-01-12
CA2335062A1 (en) 2000-02-03
NO20010291L (en) 2001-01-18

Similar Documents

Publication Publication Date Title
FI971412L (en) Peptididyl compounds and their therapeutic use as metalloprotease inhibitors
CY2016006I1 (en) COMBINED USE OF VALSARTAN AND CALCIUM CHANNEL BLOCKERS FOR THERAPEUTIC PURPOSES
NO20020635L (en) Inhibitors of protein polymerization and the methods used
NO971015D0 (en) Compounds and Methods for the Treatment of Cancer
PT977748E (en) SUBSTITUTED BENZOPIRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION
EE200100659A (en) Diaminothiazoles and their use for the inhibition of protein kinases
DE60141247D1 (en) BAND CASSETTE AND BAND UNIT
IT1308739B1 (en) TREATMENT DEVICE OF AN ELONGATED BELT
EE200000093A (en) Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
PT1206436E (en) RETINOIDS FOR THE TREATMENT OF ENFISEMA
NO20010291D0 (en) Co-administration of ACAT and MMP inhibitors for the treatment of atherosclerotic wounds
IT1277461B1 (en) PROCEDURE AND DEVICE FOR THE TREATMENT OF MATERIALS
NO20015772L (en) Compounds and methods for the treatment of post-traumatic stress syndrome
ITTO950529A0 (en) DEVICE AND PROCEDURE FOR THE CREATION OF REDUCED LENGTH ORTHODE CHAINS
DE60144529D1 (en) BAND CASSETTE AND BAND UNIT
NO994631D0 (en) Procedures and compositions for the treatment of ovarian cancer
NO20010464D0 (en) Methods and compositions for the treatment of gastroesophrageal reflux syndrome
ID28797A (en) TIOREDOXINATION AND PROCESSING OF SEEDS
EE200300057A (en) Ingredients for the prevention and treatment of cancer
NO20013651D0 (en) Use of phosphorus inorganic compounds for the prophylactic and therapeutic treatment of infections
PT1381620E (en) HYPERSULFATE DISSACIRATES AND METHODS FOR THE USE THEREOF FOR THE TREATMENT OF INFLAMMATIONS
EE05263B1 (en) The use of IL-18 inhibitors focuses on the treatment or prevention of systemic damage
NO20012612D0 (en) Isonipecotamides for the treatment of integrin-mediated disorders
PT1200447E (en) OXAZINOCARBAZOLES FOR THE TREATMENT OF DISEASES OF THE SNC
NO20010569D0 (en) Protease inhibitors for use in the treatment of psoriasis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application